Accenture and Intel Support Neuromorphic Research Project to Develop Robotic Arm for Wheelchair-Bound Pediatric Patients

Accenture and Intel are supporting a neuromorphic computing research project led by the Neuro-Biomorphic Engineering Lab (NBEL) at the Open University of Israel in collaboration with ALYN Hospital, Israel’s leading pediatric and adolescent rehabilitation center. Funded by Accenture through its participation in the Intel Neuromorphic Research Community (INRC), the project is focused on developing and testing a wheelchair-mounted robotic arm to assist patients with performing daily tasks.

Researchers from Accenture Labs and Intel Labs are working with researchers from Open University of Israel to build a wheelchair-mounted robotic arm with adaptive controls, using an algorithm developed by Applied Brain Research (ABR) and Intel’s neuromorphic computing hardware. Wheelchair users will be able to independently control the robotic arm to perform daily tasks that require strength and dexterity of arms and hands, such as drinking from a glass, with 50% fewer errors and a 48% improvement in energy efficiency over traditional control methods. The device will undergo clinical testing and evaluation with patients at ALYN Hospital who rely on electric wheelchairs and have motor impairment of their upper extremities.

Studies suggest that wheelchair-mounted robotic arms provide an increased sense of independence for users and that these assistive tools can reduce the need for caregiver time by up to 41 percent. Today, however, the cost of these devices is incredibly high, making them inaccessible to many people who need them.

“The ability of robotic arms to benefit people today is largely limited due to high cost and excessive power consumption,” said Elishai Ezra Tsur, lead project researcher at the Open University of Israel. “This funding from Accenture, along with additional support from Intel and ABR, is allowing us to explore the implementation of adaptive controls on neuromorphic hardware in an effort to address the need for a collaborative, user-friendly, accurate robotic arm at a significantly reduced cost.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”